Pharvaris (NASDAQ:PHVS) Insider Wim Souverijns Sells 6,090 Shares of Stock

Key Points

• Insider selling: Pharvaris insider Wim Souverijns sold 6,090 shares for approximately $237,449, reducing his holdings by 13.5%; he also sold 20,000 shares the previous day.
• Analyst outlook remains positive: Shares traded down 1.9% to $37.33, but analysts maintain a “Moderate Buy” consensus with an average price target near $59.87.
• Pipeline progress versus financial risk: Phase III results for oral deucrictibant showed an 83% reduction in hereditary angioedema attacks, supporting potential 2027 regulatory filings. However, Pharvaris remains unprofitable and recently reported a larger-than-expected quarterly loss of $0.81 per share.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Wim Souverijns sold 6,090 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $38.99, for a total value of $237,449.10. Following the completion of the sale, the insider owned 39,021 shares of the company's stock, valued at $1,521,428.79. This represents a 13.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Wim Souverijns also recently made the following trade(s):

• On Monday, September 14th, Wim Souverijns sold 20,000 shares of Pharvaris stock. The shares were sold at an average price of $39.31, for a total value of $786,200.00.

Pharvaris Trading Down 1.9%

Shares of NASDAQ:PHVS traded down $0.73 during mid-day trading on Wednesday, reaching $37.33. The stock had a trading volume of 426,621 shares, compared to its average volume of 403,904. The firm has a 50 day simple moving average of $35.27 and a two-hundred day simple moving average of $31.56. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25. The firm has a market cap of $2.44 billion, a PE ratio of -12.24 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities analysts anticipate that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Phase III results for once-daily extended-release deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks. The data support Pharvaris’ plans for regulatory submissions in 2027 and strengthen the commercial outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst sentiment remains favorable. The reported consensus price target increased 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. MarketBeat data shows a “Moderate Buy” consensus with an average target near $59.87. Pharvaris consensus price target raised
• Positive Sentiment: Institutional interest has expanded, with BlackRock establishing a position and Alyeska Investment Group and Seven Fleet Capital substantially increasing their holdings. Such buying can support investor confidence in PHVS.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript headline does not identify a new announcement. Morgan Stanley Global Healthcare Conference transcript
• Negative Sentiment: Insiders have been selling shares. CEO Berndt Modig sold 2,291 shares worth approximately $90,265, while President Peng Lu sold 15,000 shares and Anne Lesage sold 30,000 shares worth about $1.15 million. Lu’s transaction was intended to cover tax withholding on vested equity, somewhat reducing its negative significance, but the overall selling may weigh on sentiment. Pharvaris insider selling report
• Negative Sentiment: Pharvaris remains unprofitable and previously reported quarterly EPS of negative $0.81, below the consensus estimate of negative $0.75. Analysts expect a full-year loss of approximately $3.12 per share, underscoring continued development and financing risk.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. Wedbush boosted their target price on Pharvaris from $42.00 to $50.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. Royal Bank Of Canada lifted their price objective on shares of Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Wells Fargo & Company increased their target price on shares of Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a report on Wednesday, September 9th. Finally, Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a research note on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $59.87.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. venBio Partners LLC acquired a new stake in Pharvaris during the second quarter worth $160,569,809. Wellington Management Group LLP lifted its stake in shares of Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock valued at $82,748,000 after purchasing an additional 274,034 shares during the last quarter. Commodore Capital LP lifted its stake in shares of Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock valued at $54,211,000 after purchasing an additional 29,525 shares during the last quarter. 5AM Venture Management LLC purchased a new position in shares of Pharvaris during the 2nd quarter worth $27,581,008. Finally, Seven Fleet Capital Management LP grew its holdings in shares of Pharvaris by 144.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock worth $26,782,000 after purchasing an additional 457,804 shares during the period.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.